IRIS Accounts Production v25.4.12.37 10226176 Board of Directors 1.7.24 30.6.25 30.6.25 false true false false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 10226176 2024-06-30 10226176 2025-06-30 10226176 2024-07-01 2025-06-30 10226176 2023-06-30 10226176 2023-07-01 2024-06-30 10226176 2024-06-30 10226176 ns15:EnglandWales 2024-07-01 2025-06-30 10226176 ns14:PoundSterling 2024-07-01 2025-06-30 10226176 ns10:Director1 2024-07-01 2025-06-30 10226176 ns10:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 10226176 ns10:SmallEntities 2024-07-01 2025-06-30 10226176 ns10:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 10226176 ns10:SmallCompaniesRegimeForDirectorsReport 2024-07-01 2025-06-30 10226176 ns10:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 10226176 ns10:FullAccounts 2024-07-01 2025-06-30 10226176 1 2024-07-01 2025-06-30 10226176 ns10:Director2 2024-07-01 2025-06-30 10226176 ns10:Director3 2024-07-01 2025-06-30 10226176 ns10:Director5 2024-07-01 2025-06-30 10226176 ns10:RegisteredOffice 2024-07-01 2025-06-30 10226176 ns5:CurrentFinancialInstruments 2025-06-30 10226176 ns5:CurrentFinancialInstruments 2024-06-30 10226176 ns5:Non-currentFinancialInstruments 2025-06-30 10226176 ns5:Non-currentFinancialInstruments 2024-06-30 10226176 ns5:ShareCapital 2025-06-30 10226176 ns5:ShareCapital 2024-06-30 10226176 ns5:SharePremium 2025-06-30 10226176 ns5:SharePremium 2024-06-30 10226176 ns5:RetainedEarningsAccumulatedLosses 2025-06-30 10226176 ns5:RetainedEarningsAccumulatedLosses 2024-06-30 10226176 ns5:IntangibleAssetsOtherThanGoodwill 2024-07-01 2025-06-30 10226176 ns5:PatentsTrademarksLicencesConcessionsSimilar 2024-07-01 2025-06-30 10226176 ns5:LeaseholdImprovements 2024-07-01 2025-06-30 10226176 ns5:PlantMachinery 2024-07-01 2025-06-30 10226176 ns5:ComputerEquipment 2024-07-01 2025-06-30 10226176 ns5:PatentsTrademarksLicencesConcessionsSimilar 2024-06-30 10226176 ns5:PatentsTrademarksLicencesConcessionsSimilar 2025-06-30 10226176 ns5:PatentsTrademarksLicencesConcessionsSimilar 2024-06-30 10226176 ns5:LeaseholdImprovements 2024-06-30 10226176 ns5:PlantMachinery 2024-06-30 10226176 ns5:ComputerEquipment 2024-06-30 10226176 ns5:LeaseholdImprovements 2025-06-30 10226176 ns5:PlantMachinery 2025-06-30 10226176 ns5:ComputerEquipment 2025-06-30 10226176 ns5:LeaseholdImprovements 2024-06-30 10226176 ns5:PlantMachinery 2024-06-30 10226176 ns5:ComputerEquipment 2024-06-30 10226176 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-06-30 10226176 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-06-30

REGISTERED NUMBER: 10226176 (England and Wales)

HEXIGONE INHIBITORS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED

30 JUNE 2025

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 4 |

| HEXIGONE INHIBITORS LIMITED |

COMPANY INFORMATION

FOR THE YEAR ENDED 30 JUNE 2025

| DIRECTORS: | Dr P C Dodds

| Dr J Phoenix

| M J Owens

| C Oliver

| REGISTERED OFFICE: | Unit 11&12 Mardon Park

| Baglan Energy Park

| Baglan

| Port Talbot

| SA12 7AX

| REGISTERED NUMBER: | 10226176 (England and Wales)

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

BALANCE SHEET

30 JUNE 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 4 | 132,160 |  | 125,154 |  |

Tangible assets | 5 | 332,450 |  | 231,052 |  |

464,610 |  | 356,206 |  |

CURRENT ASSETS

Stocks | 111,378 |  | 166,611 |  |

Debtors | 6 | 128,539 |  | 171,127 |  |

Cash at bank and in hand | 25,229 |  | 371,714 |  |

265,146 |  | 709,452 |  |

CREDITORS

Amounts falling due within one year | 7 | 102,993 |  | 81,901 |  |

NET CURRENT ASSETS | 162,153 |  | 627,551 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 626,763 |  | 983,757 |  |

CREDITORS

Amounts falling due after more than one year | 8 | 547,000 |  | 547,000 |  |

NET ASSETS | 79,763 |  | 436,757 |  |

CAPITAL AND RESERVES

Called up share capital | 9 | 5,052 |  | 4,926 |  |

Share premium | 3,289,917 |  | 3,135,975 |  |

Retained earnings | (3,215,206 | ) | (2,704,144 | ) |

79,763 |  | 436,757 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

BALANCE SHEET - continued

30 JUNE 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 April 2026 and were signed on its behalf by:

Dr P C Dodds - Director

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2025

1. | STATUTORY INFORMATION

| Hexigone Inhibitors Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Patents and licences are being amortised evenly over their estimated useful life of ten years.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Improvements to property | - | 2% on cost

| Plant and Machinery | - | 15% on cost

| Computer equipment | - | 33% on cost

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

2. | ACCOUNTING POLICIES - continued

| Government grants

| Government grants towards revenue items are released to the profit and loss account when the expenditure is incurred.

| Cash at bank and cash in hand

| Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

| Debtors

| Short term debtors are measured at transaction price, less any impairment.

| Creditors

| Short term creditors are measured at transaction price.

| Provision for liabilities

| Provisions are recognised when the company has a present obligation (legal and constructive) from a past event that will probably result in a transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

| Functional and Presentation Currency

| The company's functional and presentation currency is pounds sterling.

| Going Concern

| The company has made excellent progress and is now exporting product around the world. The directors are confident they can raise the working capital required to continue the growth in the business through new investment over the coming year and on this basis the company remains a going concern.

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

2. | ACCOUNTING POLICIES - continued

| Financial instruments

| The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

| Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

| Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| Basic financial assets

| Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

| Trade debtors, loans and other receivables that have fixed or determinable payments that are not quoted in an active market are classified as 'loans and receivables'. Loans and receivables are measured at amortised cost using the effective interest method, less any impairment.

| Interest is recognised by applying the effective interest rate, except for short-term receivables when the recognition of interest would be immaterial. The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating the interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the debt instrument to the net carrying amount on initial recognition.

| Impairment of financial assets

| Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

| Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset's original effective interest rate. The impairment loss is recognised in profit or loss.

| If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

| Derecognition of financial assets

| Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

| Basic financial liabilities

| Basic financial liabilities, including trade and other payables, bank loans that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

| Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

| Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

2. | ACCOUNTING POLICIES - continued

| Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into, An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

| Derecognition of financial liabilities

| Financial liabilities are derecognised when the company's contractual obligations expire or are discharged or cancelled.

| Equity instruments

| Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

| Share Options Treatment

| The costs relating to share options have not been recognised within the accounts as the directors do not deem them material at this stage.

| Share issue costs

| The costs of raising investment within the year have been netted off against the share premium account.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 9 (2024 - 10 ) .

4. | INTANGIBLE FIXED ASSETS

| Patents

| and

| licences

£ |

| COST

| At 1 July 2024 | 151,488 |  |

| Additions | 24,616 |  |

| At 30 June 2025 | 176,104 |  |

| AMORTISATION

| At 1 July 2024 | 26,334 |  |

| Amortisation for year | 17,610 |  |

| At 30 June 2025 | 43,944 |  |

| NET BOOK VALUE

| At 30 June 2025 | 132,160 |  |

| At 30 June 2024 | 125,154 |  |

HEXIGONE INHIBITORS LIMITED (REGISTERED NUMBER: 10226176) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JUNE 2025

5. | TANGIBLE FIXED ASSETS

| Improvements |

| to |  | Plant and |  | Computer |

| property |  | Machinery |  | equipment |  | Totals

£ | £ | £ | £ |

| COST

| At 1 July 2024 | 27,034 |  | 304,233 |  | 9,216 |  | 340,483 |  |

| Additions | - |  | 155,336 |  | 713 |  | 156,049 |  |

| At 30 June 2025 | 27,034 |  | 459,569 |  | 9,929 |  | 496,532 |  |

| DEPRECIATION

| At 1 July 2024 | 2,019 |  | 101,020 |  | 6,392 |  | 109,431 |  |

| Charge for year | 540 |  | 52,108 |  | 2,003 |  | 54,651 |  |

| At 30 June 2025 | 2,559 |  | 153,128 |  | 8,395 |  | 164,082 |  |

| NET BOOK VALUE

| At 30 June 2025 | 24,475 |  | 306,441 |  | 1,534 |  | 332,450 |  |

| At 30 June 2024 | 25,015 |  | 203,213 |  | 2,824 |  | 231,052 |  |

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 59,168 |  | 97,352 |  |

| Other debtors | 69,371 |  | 73,775 |  |

128,539 |  | 171,127 |  |

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 56,193 |  | 57,640 |  |

| Taxation and social security | 20,902 |  | - |  |

| Other creditors | 25,898 |  | 24,261 |  |

102,993 |  | 81,901 |  |

8. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Other creditors | 547,000 |  | 547,000 |  |

9. | CALLED UP SHARE CAPITAL

| As of 2025, the Company has outstanding share options granted to employees, providing rights to acquire a total of 39,385 shares of the Company's common stock. These share options were issued previously and remain available for exercise under the terms of the Company’s equity compensation plan.

10. | RELATED PARTY DISCLOSURES

| The company pays consultancy fees to another company whose Director is a related party of Hexigone Inhibitors Ltd.

11. | SHARE ISSUE IN THE YEAR

| During the year the company issued 12,577 new shares at a premium and raising £154k in the process.